On December 17, the National Institutes of Health suspended the use of celecoxib COX-2 (Celebrex) for participants in a program of colorectal cancer prevention clinical trial conducted by the National Cancer Institute.
In the clinical trial patients 400 mg. Of Celebrex twice a day, 3.4 times higher risk of cardiovascular events compared to placebo. Mg for patients in study 200. Of Celebrex twice daily had a risk 2.5 times greater.
The average duration of treatment in the study was 33 months. However, a similar studies underway against 400 mg of Celebrex. Once a day versus placebo in patients followed! The same time, showed no increased risk.
On 17 December, the FDA asked Pfizer to suspend, Inc., a volunteer, the DTCA of Celebrex during the time the FDA is evaluating the new and contradictory scientific evidence of adverse events associated with drugs.
No comments:
Post a Comment